A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3

Inclusion Criteria Patients must have: * Asymptomatic HIV-1 infection. * CD4 count of 400-700 cells/mm3. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Significant illness. * Acute illness at randomization. * Hemodialysis. Prior Medication: Excluded: * Antiretroviral use within 60 days prior to study entry.